ACADIA Pharmaceuticals, Inc. (ACAD)
The Company is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders.
Recs
SmallPimpin
(98.20)
Submitted: 9/1/2009 1:00:17 PM :
Start Price:
$1.95
ACAD Score:
-42.37
Mmm...biopharmaceuticals...
Recs
BruceInToronto
(< 20)
Submitted: 8/25/2009 4:15:06 PM :
Start Price:
$6.08
ACAD Score:
-86.62
Phase three drug approval coming soon
Recs
ceccaps
(72.02)
Submitted: 8/18/2009 12:53:33 PM :
Start Price:
$5.86
ACAD Score:
-89.75
This stocks should be in the 10-12 range.
Wouldn't be surprised if it gets there by next summer.
Recs
tensaibakabon
(< 20)
Submitted: 8/12/2009 2:57:31 AM :
Start Price:
$1.85
ACAD Score:
-36.45
Phase 3 due anytime and as per the CEO will be topline results
Recs
ShortyJoy
(99.95)
Submitted: 8/1/2009 12:58:29 AM :
Start Price:
$4.40
ACAD Score:
-81.40
I believe this company is in great position . With succesfull expected test result and FDA fase 3 aproval this company might return 400-600 % in short term. It may became aqusition target and possible bidding war. August 5 earnings anounsement and onfernece call will give more light to the companies future. I believe this company is one of undervalued gems in biotec sector. Strong Buy !
Recs
Brian7992
(< 20)
Submitted: 7/29/2009 6:37:35 AM :
Start Price:
$4.24
ACAD Score:
-83.01
End of Phase III Clinical Trials and talk of Buy Out should drive this stock to new highs in the comming weeks! I see a 400 to 800% rise in price.
Recs
Brihally
(70.31)
Submitted: 6/16/2008 7:10:25 PM :
Start Price:
$4.52
ACAD Score:
-54.49
ACADIA Pharmaceuticals is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders.
Recs
Cosmo21
(< 20)
Submitted: 4/1/2008 6:42:45 PM :
Start Price:
$9.38
ACAD Score:
-69.76
ACAD is a strong buy at this level! Partnership on the way and the stock price will be back on it.s way to 17.
Recs
bobby410
(< 20)
Submitted: 12/4/2007 5:35:41 PM :
Start Price:
$11.63
ACAD Score:
-67.27
Have a friend who works there, & things are looking very very good.
Recs
sdpowell
(21.56)
Submitted: 10/29/2007 6:44:10 PM :
Start Price:
$15.16
ACAD Score:
-67.14
huge potential for the drugs they offer, good chance of being acquired by a large company too
Recs
razormd
(26.05)
Submitted: 10/17/2007 12:58:27 PM :
Start Price:
$15.25
ACAD Score:
-67.17
...I accidently had this listed as an "underperform"...I'm now correcting that...as I posted previously they have a lot of cash on hand...Allergan collaboration looks promising...pimavanserin moving steadily along...any drug development company is risky but this one looks worthy of a few seculative dollars
Recs
BRKLMB
(< 20)
Submitted: 8/22/2007 12:50:18 PM :
Start Price:
$14.93
ACAD Score:
-71.38
Upside based on likely pharma partnership before end of 2007
Recs
MCvest
(< 20)
Submitted: 7/12/2007 9:04:16 PM :
Start Price:
$13.50
ACAD Score:
-65.85
ACAD (VERY speculative, very up and down stock but I am betting on drug phase approval sending this stock up 100%)
Recs
EmpireBldr99
(50.51)
Submitted: 6/15/2007 11:23:30 AM :
Start Price:
$15.26
ACAD Score:
-67.58
Pure spec
Recs
mastiff5
(47.56)
Submitted: 6/10/2007 10:29:07 PM :
Start Price:
$14.49
ACAD Score:
-68.70
good time for pharmsss.
Recs
HaggardFrodo
(35.69)
Submitted: 4/19/2007 4:46:20 PM :
Start Price:
$14.86
ACAD Score:
-70.36
Low market cap related to potential for drug candidates. Requires patience - buy on dips
Recs
antonioexpo
(94.78)
Submitted: 3/30/2007 9:46:27 PM :
Start Price:
$14.99
ACAD Score:
-73.82
J&J concomitance will yield big bucks for all us fools
Recs
tomthebus
(< 20)
Submitted: 3/22/2007 1:17:53 PM :
Start Price:
$13.33
ACAD Score:
-72.03
intimately familar with company
Recs
daviddai
(60.22)
Submitted: 3/20/2007 2:51:36 AM :
Start Price:
$13.24
ACAD Score:
-73.87
1. More candidates!! The drug maker's positive phase 2 data is not only a prove of concept that ACP-104 targeting 5-HT receptors works on groups of schizophrenic patients while maintaining relatively safe profile, but is also indicative of the feasibility of their properitary screening platform technology. Acadia houses more than 800,000 compound in their library targeting G-coupled receptors and tyrosine receptors. Since G-coupled receptors and tyrosine kinase receptors are the most common receptors involved in psychiatric disorders, high throughput screening using their large compound library will ultimately result in more discovery in preclinical trials.
2. Buyout waiting to happen. Even though trading at $10+/share is overvalued because of the hype of clinical data, and the pivotal phase 3 clinical trial on a larger schizophrenic population is yet to be tested, I think the results has garnered attention of other pharmaceutical companies trying to get their hands on the 11 billion dollar psychiatric therapy pie. While big pharmas have neither the technology, nor the compound library for drug discovery, acquiring a small cap biotech with feasible technology will strengthen their product pipeline.
Recs
Spooky27
(87.23)
Submitted: 3/19/2007 6:18:56 PM :
Start Price:
$13.24
ACAD Score:
-73.87
This company has great protential. Plus if you consider the list of drugs that plan to come out there could be real profit here!
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 25 1 2 Next »